"A recall has been issued for the LuSys Laboratories, Inc., Ebola Virus One-Step Test Kits because the FDA has not cleared or approved the kits for use or sale," said the Food and Drug Administration in a statement emailed to reporters today.
"The results obtained from these test kits have not demonstrated to be accurate and should not be used as in vitro diagnostic tests for Ebola infection."
The recall was initially issued in mid-March and applies to test kits exported to Denmark, Sierra Leone and Canada between October 2014 and January 2015.
The FDA did not say how many tests were sent out.
The recall is described as a Class I, "the most serious type of recall and involve(s) situations in which there is a reasonable probability that use of these products will cause serious adverse health consequences or death," the FDA said.
"A false positive result may be life-threatening by potentially placing the patient in an isolation cohort with Ebola-infected patients."
Contacted by AFP, a company representative in San Diego said early trials have shown the test to be 86 percent accurate.
The problem with the FDA came down to a labeling error, he said. The equipment had not been properly labeled "for research purposes only."
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)